SCHEMBL5177286

SCHEMBL5177286

CCNC1(C(=O)O)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL842008 0.98 FFAR3 (0.35)
SCHEMBL5673887 0.91 CYP2C19 (0.35)
SCHEMBL23513707 0.91 FFAR3 (0.33)
Hydrochloric Acid SCHEMBL1706436 0.89 FFAR3 (0.32)
SCHEMBL4616715 0.89 CYP2C19 (0.39)
SCHEMBL26522481 0.83 OPRM1 (0.36)
SCHEMBL27833409 0.82 KMT2A (0.31)
Hydrochloric Acid SCHEMBL10500403 0.82 KDM4E (0.47)
SCHEMBL26497200 0.82 KDM4E (0.40)
SCHEMBL19369950 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021093817-A1 IMMUNOMODULATORY COMPOUNDS, COMPOSITION AND APPLICATION THEREOF 杭州和正医药有限公司 2021-05-20 WO disclosed
EP-2250165-B1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2018-07-25 EP disclosed
US-9770439-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-09-26 US disclosed
US-20170014408-A1 HEPATITIS B ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. 2017-01-19 US disclosed
US-20160199355-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL MAYERS SQUIBB COMPANY (US) 2016-07-14 US disclosed
US-20160158200-A1 Combinations of Hepatitis C Virus Inhibitors BRISTOL MYERS SQUIBB CO (US) 2016-06-09 US disclosed
US-9326973-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-05-03 US disclosed
US-20150297568-A1 Hepatitis C Virus Inhibitors BRISTOL MYERS SQUIBB CO (US) 2015-10-22 US disclosed
US-20150023913-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2015-01-22 US disclosed
US-20130183269-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-07-18 US disclosed
WO-2009080663-A1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO S.A. (CH) 2009-07-02 WO disclosed
WO-2009070485-A1 DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3- CARBOXYLIC ACID AMIDES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-06-04 WO disclosed
WO-2008076356-A1 NOVEL OXADIAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2008-06-26 WO disclosed
EP-1827441-A1 COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION Boehringer Ingelheim International GmbH (DE) 2007-09-05 EP disclosed
EP-1778240-A2 DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES Boehringer Ingelheim International GmbH (DE) 2007-05-02 EP disclosed
WO-2006018185-A2 DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-02-23 WO disclosed
WO-2006018182-A1 COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-02-23 WO disclosed
EP-1556361-A2 2-ALKYL-(2-AMINO-3-ARYL-PROPIONYL)-PIPERAZINE DERIVATIVES AND RELATED COMPOUNDS AS MELANOCORTIN RECEPTOR LIGANDS FOR THE TREATMENT OF OBESITY THE PROCTER & GAMBLE COMPANY (US) 2005-07-27 EP disclosed
WO-2004037797-A2 2 - ALKYL - (2 - AMINO - 3 - ARYL - PROPIONYL) - PIPERAZINE DERIVATIVES AND RELATED COMPOUNDS AS MELANOCORTIN RECEPTOR LIGANDS FOR THE TREATMENT OF OBESITY THE PROCTER & GAMBLE COMPANY (US) 2004-05-06 WO disclosed
US-6017957-A AN AMINOCYCLOPROPANECARBOXYLIC ACID OR ESTER AS POTENT DRUG TREATING NERVOUS SYSTEM DISORDER EPILEPSY, STROKE, ANXIETY, ALZHEIMER'S DISEASE, PARKINSON DISEASE, GUAM ALS, DEMENTIA, AND LATHYRISM THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2000-01-25 US disclosed